Literature DB >> 17484040

Absence of the common IGF1 19 CA-repeat allele is more common among BRCA1 mutation carriers than among non-carriers from BRCA1 families.

Maria Henningson1, Erika Bågeman, Therese Sandberg, Ake Borg, Håkan Olsson, Helena Jernström.   

Abstract

BRCA1 mutations predispose to early-onset breast cancer. We previously reported an association between absence of the common IGF1 19 CA-repeat allele (IGF1-19/-19) and being a BRCA1 mutation carrier in young women from breast cancer high-risk families. Others have reported a four-fold risk of premenopausal breast cancer in women with a family history and the IGF1-19/-19 genotype. The aim of this study was to investigate whether the IGF1-19/-19 genotype was associated with being a BRCA1 mutation carrier among women from BRCA1 families. DNA was available from 268 women with known BRCA1 status from the South Swedish Health Care Region. IGF1 genotyping was successfully performed with fragment analysis in 211 women from 96 families. The IGF1-19/-19 genotype was significantly more common among BRCA1 mutation carriers (14.2%) than among non-carriers (4.8%), OR 3.3 (95%CI 1.11-9.78, P = 0.03) adjusted for family clustering. We confirmed our previous finding of an association between the IGF1-19/-19 genotype and BRCA1 mutation status. Since the IGF1-19/-19 genotype in combination with OC use or multiparity confers an increased risk for early onset breast cancer in high-risk women and in women from the general population, future studies are needed to elucidate the importance of the IGF1-19/-19 genotype concerning the variability in breast cancer risk among BRCA1 mutation carriers.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17484040     DOI: 10.1007/s10689-007-9141-0

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  38 in total

Review 1.  BRCA1 and cell signaling.

Authors:  Q Wang; H Zhang; R Fishel; M I Greene
Journal:  Oncogene       Date:  2000-12-11       Impact factor: 9.867

2.  Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

Authors:  Steven A Narod; Marie-Pierre Dubé; Jan Klijn; Jan Lubinski; Henry T Lynch; Parviz Ghadirian; Diane Provencher; Ketil Heimdal; Pal Moller; Mark Robson; Kenneth Offit; Claudine Isaacs; Barbara Weber; Eitan Friedman; Ruth Gershoni-Baruch; Gad Rennert; Barbara Pasini; Theresa Wagner; Mary Daly; Judy E Garber; Susan L Neuhausen; Peter Ainsworth; Hakan Olsson; Gareth Evans; Michael Osborne; Fergus Couch; William D Foulkes; Ellen Warner; Charmaine Kim-Sing; Olufunmilayo Olopade; Nadine Tung; Howard M Saal; Jeffrey Weitzel; Sofia Merajver; Marion Gauthier-Villars; Helena Jernstrom; Ping Sun; Jean-Sebastien Brunet
Journal:  J Natl Cancer Inst       Date:  2002-12-04       Impact factor: 13.506

Review 3.  Toward a unified concept of mammary carcinogenesis.

Authors:  J Russo; I H Russo
Journal:  Prog Clin Biol Res       Date:  1997

4.  Total-genome analysis of BRCA1/2-related invasive carcinomas of the breast identifies tumor stroma as potential landscaper for neoplastic initiation.

Authors:  Frank Weber; Lei Shen; Koichi Fukino; Attila Patocs; George L Mutter; Trinidad Caldes; Charis Eng
Journal:  Am J Hum Genet       Date:  2006-04-12       Impact factor: 11.025

5.  Obesity, weight change, fasting insulin, proinsulin, C-peptide, and insulin-like growth factor-1 levels in women with and without breast cancer: the Rancho Bernardo Study.

Authors:  H Jernström; E Barrett-Connor
Journal:  J Womens Health Gend Based Med       Date:  1999-12

6.  Fasting glucose is a risk factor for breast cancer: a prospective study.

Authors:  Paola Muti; Teresa Quattrin; Brydon J B Grant; Vittorio Krogh; Andrea Micheli; Holger J Schünemann; Malathi Ram; Jo L Freudenheim; Sabina Sieri; Maurizio Trevisan; Franco Berrino
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-11       Impact factor: 4.254

7.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

Authors:  D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

8.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.

Authors:  D F Easton; D Ford; D T Bishop
Journal:  Am J Hum Genet       Date:  1995-01       Impact factor: 11.025

9.  Roles of CCAAT/enhancer-binding protein and its binding site on repression and derepression of acetyl-CoA carboxylase gene.

Authors:  H J Tae; X Luo; K H Kim
Journal:  J Biol Chem       Date:  1994-04-08       Impact factor: 5.157

10.  Insulin-like growth factor-1 (IGF1) genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating IGF-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families.

Authors:  H Jernström; T Sandberg; E Bågeman; A Borg; H Olsson
Journal:  Br J Cancer       Date:  2005-03-14       Impact factor: 7.640

View more
  2 in total

1.  IGF1 htSNPs in relation to IGF-1 levels in young women from high-risk breast cancer families: implications for early-onset breast cancer.

Authors:  Maria Henningson; Maria Hietala; Therese Törngren; Håkan Olsson; Helena Jernström
Journal:  Fam Cancer       Date:  2011-06       Impact factor: 2.375

2.  Comparison of radioimmuno and carbon nanotube field-effect transistor assays for measuring insulin-like growth factor-1 in a preclinical model of human breast cancer.

Authors:  Laundette P Jones; Steingrimur Stefansson; Man S Kim; Saeyoung N Ahn
Journal:  J Nanobiotechnology       Date:  2011-09-02       Impact factor: 10.435

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.